U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Starkist - 04/14/2017
  1. Warning Letters

CLOSEOUT LETTER

Starkist

Recipient:
Starkist

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
5001 Campus Drive
College Park, MD 20740 

April 14, 2017

David Calvin
Galapesca, S.A. dba StarKist Co. (Ecuador)
Km 12.5 Via a Daule, At
Reg. NO. 13117447062
Guayaquil, Guayas
Ecuador

Dear Mr. Calvin:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter September 4, 2014. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to comply and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Mildred Benjamin
Branch Chief
Food Adulteration Assessment Branch
Division of Enforcement
Office of Compliance 

Back to Top